No abstract available
Keywords:
alloimmunity; cell therapy; human leukocyte antigen (HLA); immunomodulation; immunosuppression; inflammation; rejection; transplantation.
Publication types
-
Editorial
-
Research Support, Non-U.S. Gov't
-
Comment
MeSH terms
-
Histocompatibility*
-
Transplantation Immunology*
Grants and funding
The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. GM was supported by grants from the German Federal Ministry of Education and Research (BMBF) and the German Research Foundation (DFG: EXPAND-PD project #CA2816/1) and through the BIH Center for Regenerative Therapies (BCRT) and the Berlin-Brandenburg School for Regenerative Therapies (BSRT: GSC203), respectively, and in part by the European Union’s Horizon 2020 Research and Innovation Program and the grant agreements No 733006 (PACE), 779293 (HIPGEN), 754995 (EU-TRAIN), and 101095635 (PROTO).